A Case Report with Severe Thrombocytopenia Induced by Axitinib
Ulkuhan I Koksal1, Janeiro Goffin1, Brian Lewis1
1Tulane Cancer Center, School of Medicine, Tulane University, New Orleans, LA, USA.
Abstract:
Axitinib is an oral, second-generation tyrosine kinase inhibitor that is selective for vascular endothelial growth factor receptors (VEGFR). This agent is approved as monotherapy or in combination with immune checkpoint inhibitors for the treatment of metastatic renal cell carcinoma. Axitinib is associated with a safety profile very similar to other anti-VEGFR inhibitors but usually with fewer hematologic adverse events, due to the selectivity for VEGF. In this report, we presented a rare case of grade 4 axitinib-induced thrombocytopenia, not observed with other antiangiogenic therapies. We discuss the differential diagnostic work-up, the necessary multidisciplinary approach, and the successful management of the case.
Insights
A rare case of severe axitinib-induced thrombocytopenia was observed in a patient treated for metastatic renal cell carcinoma. This study highlights the importance of monitoring for rare adverse events with anti-VEGF therapies.
Area of Science:
- Oncology
- Pharmacology
Background:
- Axitinib, a VEGFR inhibitor, treats metastatic renal cell carcinoma (mRCC).
- It is generally well-tolerated with fewer hematologic adverse events than other anti-VEGF agents.
- Its selectivity for VEGF contributes to its safety profile.
Observation:
- A rare case of grade 4 axitinib-induced thrombocytopenia is presented.
- This severe adverse event was not previously associated with axitinib or other antiangiogenic therapies.
Findings:
- The case demonstrates a rare but serious side effect of axitinib.
- Differential diagnosis and multidisciplinary management were crucial.
Implications:
- Clinicians should be vigilant for rare hematologic toxicities with axitinib.
- This case underscores the need for individualized patient monitoring in cancer therapy.
